Vimarsana
Biggest News Aggregation in the World

Page 20 - Linical Evolution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Linical Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Linical Evolution Today - Breaking & Trending Today

Women in Science: How Vida Diagnostics' Dr. Susan Wood is modernizing lung health through tech - Vimarsana News

Women in Science: How Vida Diagnostics' Dr. Susan Wood is modernizing lung health through tech

Dr. Susan Wood is CEO and president of VIDA Diagnostics. She has over 25 years of experience championing clinical intelligence solutions into routine clinical use.

Greenphire Study: Unified technology 'essential' for patient experience in clinical trials - Vimarsana News

Greenphire Study: Unified technology 'essential' for patient experience in clinical trials

Greenphire, provider of clinical trial financial solutions, has released its global 2023 State of Clinical Trial Patient Convenience Market Trends survey.

EMA publishes clinical trial plan for public health emergencies - Vimarsana News

EMA publishes clinical trial plan for public health emergencies

The EMA organized a task force made up of various stakeholders to gather insights on potential EU-level actions to improve the set up of clinical trials during public health emergencies.

Depression now one of the top five most studied disease areas in clinical development, finds Phesi - Vimarsana News

Depression now one of the top five most studied disease areas in clinical development, finds Phesi

Phesi, a global provider of patient-centric data analytics, has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date.

Neumora's depression treatment hits phase 3 after nailing phase 2 - Vimarsana News

Neumora's depression treatment hits phase 3 after nailing phase 2

An experimental antidepressant developed by Neumora Therapeutics has shown promising results in a phase 2 trial, leading the company to plan its pathway to phase 3 testing.